PMID- 20513528
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20220408
IS  - 1873-4456 (Electronic)
IS  - 0165-4608 (Linking)
VI  - 200
IP  - 1
DP  - 2010 Jul 1
TI  - Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 
      patients diagnosed between 1981 and 2008.
PG  - 8-15
LID - 10.1016/j.cancergencyto.2010.03.004 [doi]
AB  - The detection of chromosome abnormalities by conventional cytogenetics, now 
      combined with analyses using fluorescence in situ hybridization (FISH), is an 
      important component in assessing the risk stratification of acute lymphoblastic 
      leukemia (ALL). Identification of specific chromosome abnormalities led to the 
      recognition of genetic subgroups based on modal chromosomal number, reciprocal 
      translocations in B-cell ALL, or both. We report here the cytogenetic analysis of 
      208 patients with pre-B and B-cell ALL referred to a single laboratory between 
      1981 and 2008. Chromosome abnormalities were observed in 82.9% of L1/L2 ALL 
      patients and in 83.3% of L3 patients with successful analysis at diagnosis. The 
      proportion of diploid karyotypes tended to decrease during the period of study, 
      from 26% to 13%, in association with technical progress and the introduction of 
      FISH techniques. As previously reported, the incidence of high hyperdiploidy 
      (51-67 chromosomes) was higher among children, whereas pseudodiploidy and 
      hypodiploidy were higher among those >15 years of age. Structural chromosome 
      abnormalities were more frequently observed among patients older than 15 years 
      than in children (75.9% vs. 68.5%, respectively). As previously reported, 
      t(9;22)(q34;q11) and t(12;21)(p13;q21) were the most frequent structural 
      rearrangements among adults (26.9%) and children (19.7%), respectively. Almost 
      17% of the patients studied at diagnosis had further cytogenetic analyses at 
      relapse, the majority showing clonal evolution toward a more complex karyotype. 
      Although the detection of chromosome abnormalities by conventional cytogenetics 
      and FISH techniques is an important tool in assessing risk stratification of ALL, 
      some patients lack abnormalities with clinical relevance. The use of array 
      comparative genomic hybridization (aCGH) offers an alternative for identifying 
      copy number alterations, but cannot detect balanced chromosomal rearrangements.
CI  - 2010 Elsevier Inc. All rights reserved.
FAU - De Braekeleer, Etienne
AU  - De Braekeleer E
AD  - University of Western Brittany, Brest, France.
FAU - Basinko, Audrey
AU  - Basinko A
FAU - Douet-Guilbert, Nathalie
AU  - Douet-Guilbert N
FAU - Morel, Frederic
AU  - Morel F
FAU - Le Bris, Marie-Josee
AU  - Le Bris MJ
FAU - Berthou, Christian
AU  - Berthou C
FAU - Morice, Patrick
AU  - Morice P
FAU - Ferec, Claude
AU  - Ferec C
FAU - De Braekeleer, Marc
AU  - De Braekeleer M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Genet Cytogenet
JT  - Cancer genetics and cytogenetics
JID - 7909240
RN  - 0 (KMT2A protein, human)
RN  - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - *Chromosome Aberrations
MH  - Histone-Lysine N-Methyltransferase
MH  - Humans
MH  - Leukemia, B-Cell/*genetics
MH  - Middle Aged
MH  - Myeloid-Lymphoid Leukemia Protein/genetics
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*genetics
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
MH  - Recurrence
MH  - Time Factors
MH  - Translocation, Genetic
EDAT- 2010/06/02 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/06/02 06:00
PHST- 2009/10/25 00:00 [received]
PHST- 2010/02/22 00:00 [revised]
PHST- 2010/03/17 00:00 [accepted]
PHST- 2010/06/02 06:00 [entrez]
PHST- 2010/06/02 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - S0165-4608(10)00116-0 [pii]
AID - 10.1016/j.cancergencyto.2010.03.004 [doi]
PST - ppublish
SO  - Cancer Genet Cytogenet. 2010 Jul 1;200(1):8-15. doi: 
      10.1016/j.cancergencyto.2010.03.004.